Aktis Oncology (NASDAQ:AKTS – Get Free Report) has been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $34.00.
A number of analysts have recently weighed in on AKTS shares. Weiss Ratings downgraded Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, June 9th. William Blair assumed coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Raymond James Financial assumed coverage on Aktis Oncology in a report on Monday. They set a “strong-buy” rating and a $40.00 price target for the company. Finally, HC Wainwright boosted their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd.
Check Out Our Latest Stock Report on AKTS
Aktis Oncology Stock Up 9.4%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The firm had revenue of $1.87 million during the quarter. On average, research analysts expect that Aktis Oncology will post -1.62 earnings per share for the current year.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Articles
- Five stocks we like better than Aktis Oncology
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
